english Icono del idioma   español Icono del idioma  

Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/20.500.12008/52316 Cómo citar
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorBaena, Armando-
dc.contributor.authorPaolino, Melisa-
dc.contributor.authorVillarreal-Garza, Cynthia-
dc.contributor.authorTorres, Gabriela-
dc.contributor.authorDelgado, Lucía-
dc.contributor.authorRuiz, Rossana-
dc.contributor.authorCanelo-Aybar, Carlos-
dc.contributor.authorYang, Song-
dc.contributor.authorFeliu, Adriana-
dc.contributor.authorMaza, Mauricio-
dc.contributor.authorJeronimo, Jose-
dc.contributor.authorEspina, Carolina-
dc.contributor.authorAlmonte, Maribel-
dc.coverage.spatialAMÉRICA LATINAes
dc.coverage.spatialCARIBEes
dc.date.accessioned2025-11-03T17:22:25Z-
dc.date.available2025-11-03T17:22:25Z-
dc.date.issued2023-
dc.identifier.citationBaena A, Paolino M, Villarreal-Garza C y otros. Latin America and the Caribbean Code Against Cancer 1st Edition: Medical interventions including hormone replacement therapy and cancer screening. Cancer Epidemiology [en línea]. 2023;86. 13 p.es
dc.identifier.issn1877-783X-
dc.identifier.urihttps://hdl.handle.net/20.500.12008/52316-
dc.description.abstractProstate, breast, colorectal, cervical, and lung cancers are the leading cause of cancer in Latin America and the Caribbean (LAC) accounting for nearly 50% of cancer cases and cancer deaths in the region. Following the IARC Code Against Cancer methodology, a group of Latin American experts evaluated the evidence on several medical interventions to reduce cancer incidence and mortality considering the cancer burden in the region. A recommendation to limit the use of HRT was issued based on the risk associated to develop breast, endometrial, and ovarian cancer and on growing concerns related to the over-the-counter and without prescription sales, which in turn bias estimations on current use in LAC. In alignment with WHO breast and cervical cancer initiatives, biennial screening by clinical breast examination (performed by trained health professionals) from the age of 40 years and biennial screening by mammography from the age of 50 years to 74, as well as cervical screening by HPV testing (either self-sampling or provider-sampling) every 5-10 years for women aged 30-64 years, were recommended. The steadily increasing rates of colorectal cancer in LAC also led to recommend colorectal screening by occult blood testing every two years or by endoscopic examination of the colorectum every 10 years for both men and women aged 50-74 years. After evaluating the evidence, the experts decided not to issue recommendations for prostate and lung cancer screening; while there was insufficient evidence on prostate cancer mortality reduction by prostate-specific antigen (PSA) testing, there was evidence of mortality reduction by low-dose computed tomography (LDCT) targeting high-risk individuals (mainly heavy and/or long-term smokers) but not individuals with average risk to whom recommendations of this Code are directed. Finally, the group of experts adapted the gathered evidence to develop a competency-based online microlearning program for building cancer prevention capacity of primary care health professionals.es
dc.format.extent13 p.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenes
dc.relation.ispartofCancer Epidemiology. 2023;86es
dc.rightsLas obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad de la República.(Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014)es
dc.subjectCancer preventiones
dc.subjectCancer screening and early diagnosises
dc.subjectCode Against Canceres
dc.subjectHormone replacement therapy usees
dc.subjectLatin America and the Caribbeanes
dc.subject.otherNEOPLASIAS DE LA MAMAes
dc.subject.otherPREVENCIÓN DE ENFERMEDADESes
dc.subject.otherEPIDEMIOLOGÍAes
dc.subject.otherDETECCIÓN PRECOZ DEL CÁNCERes
dc.subject.otherNEOPLASIAS ENDOMETRIALESes
dc.subject.otherMUJERESes
dc.subject.otherTRERAPIA DE REEMPLAZO DE HORMONASes
dc.subject.otherNEOPLASIAS DEL CUELLO UTERINOes
dc.titleLatin America and the Caribbean Code Against Cancer 1st Edition: Medical interventions including hormone replacement therapy and cancer screeninges
dc.typeArtículoes
dc.contributor.filiacionBaena Armando, International Agency for Research on Cancer (Francia)-
dc.contributor.filiacionPaolino Melisa, Consejo Nacional de Investigaciones Científicas y Técnicas (Argentina)-
dc.contributor.filiacionVillarreal-Garza Cynthia, Hospital Zambrano Hellion - TecSalud (México)-
dc.contributor.filiacionTorres Gabriela, Instituto Nacional de Salud Pública (México)-
dc.contributor.filiacionDelgado Lucía, Universidad de la República (Uruguay). Facultad de Medicina-
dc.contributor.filiacionRuiz Rossana, Instituto Nacional de Enfermedades Neoplásicas (Perú)-
dc.contributor.filiacionCanelo-Aybar Carlos, Biomedical Research Institute Sant Pau (Barcelona)-
dc.contributor.filiacionYang Song, Biomedical Research Institute Sant Pau (Barcelona)-
dc.contributor.filiacionFeliu Adriana, International Agency for Research on Cancer (Francia)-
dc.contributor.filiacionMaza Mauricio, Pan American Health Organization (E.E.U.U.)-
dc.contributor.filiacionJeronimo Jose, National Institutes of Health (E.E.U.U.)-
dc.contributor.filiacionEspina Carolina, International Agency for Research on Cancer (Francia)-
dc.contributor.filiacionAlmonte Maribel, International Agency for Research on Cancer (Francia)-
dc.rights.licenceLicencia Creative Commons Atribución (CC - By 4.0)es
dc.identifier.doi10.1016/j.canep.2023.102446-
Aparece en las colecciones: Publicaciones Académicas y Científicas - Facultad de Medicina

Ficheros en este ítem:
Fichero Descripción Tamaño Formato   
Latin America and the Caribbean Code Against Cancer.pdfLatin America and the Caribbean Code Against Cancer8,33 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons